Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide-Reference-Cited by-同舟云学术

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

Published:2018-08 Issue:2 Volume:74 Page:218-225
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Antonarakis Emmanuel S.,Lu Changxue,Luber Brandon,Liang Chao,Wang Hao,Chen Yan,Silberstein John L.,Piana Danilo,Lai Zhao,Chen Yidong,Isaacs William B.,Luo Jun

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. Familial risk and heritability of cancer among twins in Nordic countries;Mucci;JAMA,2016

2. Inherited DNA-repair gene mutations in men with metastatic prostate cancer;Pritchard;N Engl J Med,2016

3. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer;Annala;Eur Urol,2017

4. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer;Castro;Eur Urol,2015

5. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death;Na;Eur Urol,2017

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency;Urology Case Reports;2024-11

2. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC);Urologic Oncology: Seminars and Original Investigations;2024-10

3. Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race;ClinicoEconomics and Outcomes Research;2024-09

4. Cancer de prostate métastatique résistant à la castration et inhibiteurs de PARP : de la génomique tumorale aux nouvelles associations thérapeutiques;Bulletin du Cancer;2024-09

5. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations;The Oncologist;2024-06-17